PL3352734T3 - Leczenie łysienia plackowatego - Google Patents

Leczenie łysienia plackowatego

Info

Publication number
PL3352734T3
PL3352734T3 PL16775134T PL16775134T PL3352734T3 PL 3352734 T3 PL3352734 T3 PL 3352734T3 PL 16775134 T PL16775134 T PL 16775134T PL 16775134 T PL16775134 T PL 16775134T PL 3352734 T3 PL3352734 T3 PL 3352734T3
Authority
PL
Poland
Prior art keywords
treatment
alopecia areata
areata
alopecia
Prior art date
Application number
PL16775134T
Other languages
English (en)
Polish (pl)
Inventor
Michael Sierra
Tord Labuda
Atsuo Tanimoto
Yuichi Shinozaki
Original Assignee
Leo Pharma A/S
Japan Tobacco Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2015190849A external-priority patent/JP2017066061A/ja
Application filed by Leo Pharma A/S, Japan Tobacco Inc. filed Critical Leo Pharma A/S
Publication of PL3352734T3 publication Critical patent/PL3352734T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL16775134T 2015-09-24 2016-09-22 Leczenie łysienia plackowatego PL3352734T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15186644 2015-09-24
JP2015190849A JP2017066061A (ja) 2015-09-29 2015-09-29 円形脱毛症治療剤
EP16775134.6A EP3352734B1 (en) 2015-09-24 2016-09-22 Treatment of alopecia areata
PCT/EP2016/072531 WO2017050891A1 (en) 2015-09-24 2016-09-22 Treatment of alopecia areata

Publications (1)

Publication Number Publication Date
PL3352734T3 true PL3352734T3 (pl) 2020-08-24

Family

ID=57047187

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16775134T PL3352734T3 (pl) 2015-09-24 2016-09-22 Leczenie łysienia plackowatego

Country Status (27)

Country Link
US (3) US20180263986A1 (enExample)
EP (1) EP3352734B1 (enExample)
JP (1) JP6776345B2 (enExample)
KR (1) KR102728341B1 (enExample)
CN (1) CN108135834B (enExample)
AU (3) AU2016325388A1 (enExample)
BR (1) BR112018005771B1 (enExample)
CA (1) CA2998972A1 (enExample)
CY (1) CY1122837T1 (enExample)
DK (1) DK3352734T3 (enExample)
ES (1) ES2779762T3 (enExample)
HR (1) HRP20200472T1 (enExample)
HU (1) HUE049052T2 (enExample)
IL (3) IL312861A (enExample)
LT (1) LT3352734T (enExample)
MX (1) MX375024B (enExample)
MY (1) MY196541A (enExample)
PL (1) PL3352734T3 (enExample)
PT (1) PT3352734T (enExample)
RS (1) RS60365B1 (enExample)
RU (1) RU2754997C2 (enExample)
SG (1) SG10202111361TA (enExample)
SI (1) SI3352734T1 (enExample)
TW (1) TWI720022B (enExample)
UA (1) UA124192C2 (enExample)
WO (1) WO2017050891A1 (enExample)
ZA (1) ZA201801722B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021132598A1 (ja) * 2019-12-27 2021-07-01 ロート製薬株式会社 水性組成物
WO2023029943A1 (zh) * 2021-09-03 2023-03-09 星药科技(北京)有限公司 一种芳杂环化合物及其制备方法和用途
JP2025514747A (ja) * 2022-04-20 2025-05-09 レオ ファーマ アクティーゼルスカブ 前頭部線維性脱毛症の治療

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
US8637569B2 (en) * 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
EP3061455B1 (en) * 2013-10-21 2018-11-28 Japan Tobacco, Inc. Therapeutic agent for ocular disease or prophylactic agent for ocular disease

Also Published As

Publication number Publication date
RU2754997C2 (ru) 2021-09-08
EP3352734B1 (en) 2020-01-15
SG10202111361TA (en) 2021-12-30
TWI720022B (zh) 2021-03-01
ES2779762T3 (es) 2020-08-19
KR20180054767A (ko) 2018-05-24
JP2018528238A (ja) 2018-09-27
AU2024204716A1 (en) 2024-07-25
NZ740690A (en) 2024-11-29
IL298520A (en) 2023-01-01
DK3352734T3 (da) 2020-03-30
CN108135834A (zh) 2018-06-08
MX2018003332A (es) 2018-08-16
AU2016325388A1 (en) 2018-03-29
RU2018114922A (ru) 2019-10-28
IL312861A (en) 2024-07-01
EP3352734A1 (en) 2018-08-01
CA2998972A1 (en) 2017-03-30
MX375024B (es) 2025-03-06
PT3352734T (pt) 2020-03-31
US20180263986A1 (en) 2018-09-20
UA124192C2 (uk) 2021-08-04
KR102728341B1 (ko) 2024-11-11
ZA201801722B (en) 2025-06-25
HRP20200472T1 (hr) 2020-09-18
RS60365B1 (sr) 2020-07-31
TW201717955A (zh) 2017-06-01
HUE049052T2 (hu) 2020-09-28
HK1257770A1 (en) 2019-10-25
JP6776345B2 (ja) 2020-10-28
US20240398809A1 (en) 2024-12-05
BR112018005771B1 (pt) 2023-12-05
AU2022202508A1 (en) 2022-05-12
WO2017050891A1 (en) 2017-03-30
CY1122837T1 (el) 2021-05-05
LT3352734T (lt) 2020-04-10
BR112018005771A2 (pt) 2018-10-09
SI3352734T1 (sl) 2020-07-31
RU2018114922A3 (enExample) 2019-12-11
CN108135834B (zh) 2021-07-27
IL257918A (en) 2018-05-31
US20220088020A1 (en) 2022-03-24
MY196541A (en) 2023-04-19

Similar Documents

Publication Publication Date Title
IL285151B1 (en) Methods for the treatment of fgf21-related disorders
ZA202006746B (en) Methods of treatment
ZA201804227B (en) Methods of treating cancer
IL255189A0 (en) Cancer treatment methods
ZA201705673B (en) Methods for treating skin
IL257509A (en) Biomarkers for the treatment of alopecia areata
SG11201706729SA (en) Derivatives of sobetirome
ZA201706059B (en) Method of treatment with tradipitant
ZA201706257B (en) Treatment of wood
PL3964213T3 (pl) Leczenie zaburzeń zachowania
IL290855A (en) Treatment methods using vitamin d
ZA201506534B (en) Method of treating hair
IL254825A0 (en) Methods of treatment with Tesalisib
ZA201705847B (en) Treatment of pain
GB201904142D0 (en) Improved method of FT-IMS
IL253847A0 (en) Methods of treating diseases
IL257918A (en) Treatment of regional baldness
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
GB201602802D0 (en) Method of treatment
GB201512139D0 (en) Methods of treatment
GB201510870D0 (en) Treatment of infarction
GB201511017D0 (en) Method of treatment
GB201512723D0 (en) Treatment of cancer
GB201507928D0 (en) Treatment of cancer
GB201504617D0 (en) Treatment of cancer